Bevacizumab (anti-VEGF)

製品コード：A2006         Batch: A200606

印刷

Bevacizumab (anti-VEGF, Avastin) is a humanized anti-VEGF monoclonal antibody which binds to and neutralizes all human VEGF-A isoforms and bioactive proteolytic fragments, MW:149 KD.

製品説明

CAS No. 216974-75-3
Formulation PBS buffer, pH 7.2
Isotype Human IgG1
Source CHO cells
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles
Shipping Shipped under low temperature conditions
Purity 99%
Protein concentration 4.973mg/ml
Endotoxin Level ＜1EU/mg

カスタマーフィードバック

数据来源于[Data independently produced by , , Cancer Lett, 2018, 439:78-90]

VEGFA expression in the indicated cells treated with or without bevacizumab or transfected with VEGFA or shVEGFA.

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Engineered receptors for soluble cellular communication and disease sensing [ Nature, 2025, 638(8051):805-813] PubMed: 39542025
Tumor Explants Elucidate a Cascade of Paracrine SHH, WNT, and VEGF Signals Driving Pancreatic Cancer Angiosuppression [ Cancer Discov, 2024, 14(2):348-361] PubMed: 37966260
Leukemic stem cells activate lineage inappropriate signalling pathways to promote their growth [ Nat Commun, 2024, 15(1):1359] PubMed: 38355578
Engineered therapeutic antibodies with mannose 6-phosphate analogues as a tool to degrade extracellular proteins [ Front Immunol, 2024, 15:1273280] PubMed: 38533506
Bevacizumab increases the sensitivity of olaparib to homologous recombination-proficient ovarian cancer by suppressing CRY1 via PI3K/AKT pathway [ Front Oncol, 2024, 14:1302850] PubMed: 38420012
Interferon-regulatory factor-1 boosts bevacizumab cardiotoxicity by the vascular endothelial growth factor A/14-3-3γ axis [ ESC Heart Fail, 2024, 11(2):986-1000] PubMed: 38234115
Interferon-regulatory factor-1 boosts bevacizumab cardiotoxicity by the vascular endothelial growth factor A/14-3-3γ axis [ ESC Heart Fail, 2024, 10.1002/ehf2.14640] PubMed: 38234115
14K prolactin derived 14-mer antiangiogenic peptide targets bradykinin-/nitric oxide-cGMP-dependent angiogenesis [ FEBS Open Bio, 2024, 14(12):2072-2085] PubMed: 39312470
Tumor Explants Elucidate a Cascade of Paracrine SHH, WNT, and VEGF Signals Driving Pancreatic Cancer Angiosuppression [ Cancer Discov, 2024, 14(2):348-361] PubMed: 37966260
EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade [ Cancer Immunol Res, 2023, 11(11):1493-1507] PubMed: 37728484

人間や獣医の診断であるか治療的な使用のためにでない。